Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study
Seamus Kent, Philani Mpofu, Stephen Duffield, Jane Adam, Brennan Beal, Trevor J Royce, Blythe Adamson, Jyotsna Kasturi, Arun Sujenthiran, Páll Jónsson · 2024
Read Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study by Seamus Kent, Philani Mpofu, Stephen Duffield, Jane Adam, Brennan Beal, Trevor J Royce, Blythe Adamson, Jyotsna Kasturi, Arun Sujenthiran, Páll Jónsson (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11628978.txt.
Description
Kent and a large team ask in twenty twenty-four whether survival results from the United States can stand in for the United Kingdom in judging lung cancer drugs. The cancer type is advanced lung cancer of the most common form, treated first with chemo, immune, or targeted drugs. Health bodies often face thin local data when they weigh new treatments.
The team compared about one thousand UK patients with several thousand US patients from health records. After adjusting the US group to match the UK group, survival was much alike for each drug class. Curves for immune and targeted drugs nearly overlapped. The authors say US data could fill gaps in UK reviews where local data are sparse.
Catalog record
| CREATOR | Seamus Kent, Philani Mpofu, Stephen Duffield, Jane Adam, Brennan Beal, Trevor J Royce, Blythe Adamson, Jyotsna Kasturi, Arun Sujenthiran, Páll Jónsson |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |